Pekka J. Hannonen

Jyvaeskylae, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Limited reduction of bone mineral density in patients with early rheumatoid arthritis receiving aggressive treatment: 10 year results of the NEO-RACo study.

Limited reduction of bone mineral density in patients with early rheumatoid arthritis receiving aggressive treatment: 10 year results of the NEO-RACo study.

Journal: Scandinavian journal of rheumatology

Published: June 23, 2025

Real-world data on seropositive rheumatoid arthritis, then and now: ten-year outcomes of 1151 patients diagnosed between 1997 and 2011.

Real-world data on seropositive rheumatoid arthritis, then and now: ten-year outcomes of 1151 patients diagnosed between 1997 and 2011.

Journal: Clinical and experimental rheumatology

Published: February 28, 2022

Erratum to: Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study.

Erratum to: Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study.

Journal: Rheumatology (Oxford, England)

Published: February 11, 2021

Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study.

Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study.

Journal: Rheumatology (Oxford, England)

Published: May 24, 2020

Cervical Spine Involvement among Patients with Rheumatoid Arthritis Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study.

Cervical Spine Involvement among Patients with Rheumatoid Arthritis Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study.

Journal: The Journal of rheumatology

Published: November 05, 2019

Prevalence of calcium pyrophosphate deposition disease in a cohort of patients diagnosed with seronegative rheumatoid arthritis.

Prevalence of calcium pyrophosphate deposition disease in a cohort of patients diagnosed with seronegative rheumatoid arthritis.

Journal: Clinical and experimental rheumatology

Published: December 03, 2018

Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial.

Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial.

Journal: Arthritis care & research

Published: March 13, 2018

Does early seronegative arthritis develop into rheumatoid arthritis? A 10-year observational study.

Does early seronegative arthritis develop into rheumatoid arthritis? A 10-year observational study.

Journal: Clinical and experimental rheumatology

Published: January 02, 2018

Survival and safety of infliximab bio-original and infliximab biosimilar (CT-P13) in usual rheumatology care.

Survival and safety of infliximab bio-original and infliximab biosimilar (CT-P13) in usual rheumatology care.

Journal: Clinical and experimental rheumatology

Published: December 12, 2017

Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.

Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.

Journal: Scandinavian journal of rheumatology

Published: April 04, 2017

Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.

Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.

Journal: PloS one

Published: October 28, 2016

What have biological drugs changed in inflammatory rheumatic, skin and bowel diseases?

What have biological drugs changed in inflammatory rheumatic, skin and bowel diseases?

Journal: Duodecim; laaketieteellinen aikakauskirja

Published: March 29, 2016

Showing 1-12 of 34

Last Updated: 09/26/2026